MBRX
USDMoleculin Biotech Inc. Common Stock
Reaalajas hind
Hinnagraafik
Põhinäitajad
Turunäitajad
Avatud
$0.483
Kõrge
$0.502
Madal
$0.470
Maht
2.28M
Ettevõtte fundamentaalnäitajad
Turukapitalisatsioon
24.6M
Tööstusharu
Biotehnoloogia
Riik
United States
Kauplemisstatistika
Keskmine maht
4.00M
Börs
NCM
Valuuta
USD
52 nädala vahemik
Seotud uudised
Moleculin to Highlight its Ongoing Phase 3 Acute Myeloid Leukemia "MIRACLE" Clinical Trial at the 14th Annual Acute Leukemia Meeting
HOUSTON, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat
Moleculin Expands Global IP Portfolio with New Australian Patent for Annamycin
HOUSTON, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat
Moleculin Announces New Investigator-Initiated Study of Annamycin for Treating Pancreatic Cancer
Atlantic Health, a leading provider of health care based in New Jersey, to conduct the investigator-initiated Phase 1B/2 study Preclinical studies indicate Annamycin targets key factors in pancreatic cancer HOUSTON,
Beyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat Conditions
Equity InsiderNews Commentary – Conventional small molecule approaches have struggled to address genetic defects and complex disease mechanisms,...
Seotud aktsiad
ATLCP
Atlanticus Holdings Corporation 7.625% Series B Cumulative Perpetual Preferred Stock no par value per share
IGD
Voya Global Equity Dividend and Premium Opportunity Fund
HBI
Hanesbrands Inc.
THTX
Theratechnologies Inc. Common Shares
PAYS
Paysign Inc.
Püsi kursis
Määrake hinnateavitused, hankige tehisintellekti analüüsi uuendusi ja reaalajas turuuudiseid.